This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
PROfound
VISION Trial
mHSPC
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
ADSTILADRIN
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
ECLIPSE
ESCAPE
FORT
NRG-GU 0101
Masofaniten (EPI-7386)
METANOVA
RTIRE
SHORTER
Right Side
PCCTC
DORA
IRONMAN
PROMISE
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Petros Grivas, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Sumanta (Monty) Kumar Pal, MD
Jaime Landman, MD
Prostate Cancer
Advanced Prostate Cancer
Alicia Morgans, MD, MPH
CRPC with Bone Metastases
Rana R. McKay, MD
Imaging Center
Phillip Koo, MD
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
mHSPC
Alicia Morgans, MD, MPH
nmCRPC
Alicia Morgans, MD, MPH
PSMA-Targeted Therapy
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular, Penile, and Rare GU Malignancies
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
SESAUA 2024
Southern CA GU Cancer Research Forum 2024
AUA Urology Advocacy Summit 2024
ASCO GU 2024
2024 UCSF-UCLA PSMA Conference
SUO 2023
All Conferences
View All
PCF
UroToday Home
Conference Highlights
ASCO GU 2018
ASCO GU 2018
Prostate Cancer
Bladder Cancer
Renal Cancer
Penile, Urethral, Testicular and Adrenal Cancers
Press
ASCO GU 2018 Bladder Cancer
Viewing 21-40 of 45 articles
ASCO GU 2018: The Role of Metastatic Burden in Cytoreductive/Consolidative Radical Cystectomy
ASCO GU 2018: Using Grade of Tumor Recurrence After BCG to Guide Further Therapy
ASCO GU 2018: Best of Journals: Urothelial Carcinoma – Translational Science
ASCO GU 2018: Best of Journals: Urothelial Carcinoma
ASCO GU 2018: Next Generation Sequencing of Urothelial Bladder Cancer: Memorial Sloan Kettering Cancer Center Experience in 454 Patients
ASCO GU 2018: Real-world Survival and Treatment Patterns of Patients with Locally Advanced or Metastatic Urothelial Carcinoma Treated with Second-line Therapy After Platinum-based Chemotherapy
ASCO GU 2018: The impact of neoadjuvant chemotherapy on conditional survival among patients with muscle-invasive bladder cancer
ASCO GU 2018: Distress Prevalence and Associated Risk Factors within the Urothelial Cancer Population
ASCO GU 2018: Avelumab as Neoadjuvant Therapy in Subjects with Muscle-invasive Urothelial Carcinoma - AURA Trial
ASCO GU 2018: Immune Checkpoint Inhibitors: Which One and Why?
ASCO GU 2018: Two-year Follow-up: 3 KEYNOTE-045 Trial of Pembrolizumab vs Investigator’s Choice Chemotherapy in Recurrent, Advanced Urothelial Cancer
ASCO GU 2018: New 6-factor prognostic model for patients with advanced urothelial carcinoma receiving post-platinum atezolizumab
ASCO GU 2018: Atezolizumab vs. Chemotherapy in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma - Outcomes from the Phase III IMvigor211 Study
ASCO GU 2018: Nivolumab Monotherapy in Metastatic Urothelial Carcinoma: Longer-term Efficacy and safety Results from the CheckMate 032 Study
ASCO GU 2018: A Genomic Classifier for Identifying a Neuroendocrine-like Bladder Cancer Subtype
ASCO GU 2018: Preliminary results from patients with urothelial carcinoma in a phase 1A/1B study of bgb-A317, an anti-PD-1 monoclonal antibody
ASCO GU 2018: Results of Phase I Plus Expansion Cohorts of Cabozantinib Plus Nivolumab and Cabozantinib/nivolumab Plus Ipilimumab In Patients With Metastatic Urothelial Carcinoma And Other Genitourinary Malignancies
ASCO GU 2018: Lessons Learned From New Guidelines and How They Have Changed Management of Muscle-Invasive Bladder Cancer
ASCO GU 2018: Between-surgeon variation in surgical quality performance as an indicator of outcomes in radical cystectomy for bladder cancer
ASCO GU 2018: Differences in survival among non-urothelial bladder cancers: Analyses of SEER 1988-2008
1
2
3
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free